Tandem Diabetes Care Stock (NASDAQ: TNDM)

Dernières nouvelles pour Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care Inc

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to &#8220;Attractive,&#8221; believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
However, this view didn&#8217;t play out as expected, mainly due to unforeseen, company-specific issues, such as DexCom, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) unexpected <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39988466/dexcom-faces-short-term-challenges-but-market-growth-prospects-remain-strong-analys" rel="noreferrer noopener">Q2 channel mix challenges</a>, Edwards Lifesciences Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39967649/edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business" rel="noreferrer noopener">slowdown in TAVR procedures</a>, TransMedics Group, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" rel="noreferrer noopener">seasonal impacts</a>, and iRhythm Technologies, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" rel="noreferrer noopener">DOJ investigation</a>.
Morgan Stanley is bullish on the MedTech industry as volumes and pipelines continue to be strong into 2025 despite a shakey 2024.
The analyst also adds that MedTech seems less exposed to potential delays from extended FDA regulatory pathways than other healthcare sectors, given its lower reliance on PMAs and clinical-trial-heavy products.
The analyst adds that while single-stock surprises are inevitable, the overall outlook for the sector heading into 2025 remains favorable.
Morgan Stanley upgraded the outlook on Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), moving both to Overweight from Equal-weight, citing:
<ul>
<li>ISRG: Strong demand for the Da Vinci Dv5 system is expected to exceed market expectations for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noreferrer noopener">installed base growth</a>.</li>
<li>SYK: While orthopedic procedure volumes face some uncertainty, an estimated $1 billion—$2 billion backlog could drive growth in 2025. The company also benefits from ongoing M&amp;A opportunities <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40819730/stryker-unveils-new-foot-ankle-solutions-with-truss-implants-details" target="_blank" rel="noreferrer noopener">and product innovations</a>.</li>
</ul>
Additional updates:
<ul>
<li>Procept BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>): Initiated at Overweight, driven by increasing demand and higher pricing for Hydros in operating room efficiency, particularly in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">lower-volume BPH centers</a>.</li>
<li>Tandem Diabetes Care Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>): Upgraded to Overweight with a $45 price target, as its valuation (below 2x sales) seems overly compressed. Expansion into type 2 diabetes in 2025 could double its <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">total addressable market</a>.</li>
<li>Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>): Upgraded to Overweight with a $100 price target as merger concerns ease and strong above-market growth persists.</li>
<li>Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>): Raised to Equal-weight from Underweight, factoring in the discontinuation of certain risks and potential upside from GLP-1 <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">pen needle demand</a>.</li>
</ul>
The analyst is more cautious about Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), downgrading it to Underweight from Equal-weight. The analyst notes that iDose is a strong product with promising long-term potential, but the current valuation limits the upside compared to other stocks. Additionally, although the pipeline includes exciting projects like Wet AMD, they remain <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752463/glaukos-reports-30-boost-in-glaucoma-sales-improved-margins-in-q3-analyst-highlights-certain-headwi" rel="noreferrer noopener">years away from fruition</a>.
Morgan Stanley has downgraded Nevro Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) to Underweight from Equal-weight. Despite trading near record lows, the analyst expects weak demand for spinal cord stimulation devices to persist, with limited <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41910770/why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday" rel="noreferrer noopener">opportunities for cost reductions</a>.
The analyst remains cautious about STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>). While the company is executing well, it faces tough conditions in the refractive surgery market, particularly in China and the U.S.
Lastly, Morgan Stanley is cautious about Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) because it offers fewer upside opportunities than peers and has a more conservative outlook <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook" rel="noreferrer noopener">on operating margins</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42270388/marvell-and-aws-deepen-collaboration-on-cloud-and-ai-solutions-driving-stock-surge-ahead-of-q3-earnings" target="_blank" rel="noreferrer noopener">Marvell And AWS Deepen Collaboration On Cloud And AI Solutions: Details</a></li>
</ul>
Photo by metamorworks via Shutterstock

Analyst Color

Biotech

News

Upgrades

Downgrades

Health Care

Analyst Ratings

Movers

Trading Ideas

General

DXCM

EMBC

GKOS

GMED

IRTC

ISRG

NVRO

PRCT

STAA

TMDX

TNDM

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

WIIM

Tandem Diabetes Care shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.

In the latest quarter, 8 analysts provided ratings for Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Tandem Diabetes Care, presenting an average target of $49.5, a high estimate of $65.00, and a low estimate of $37.00. Marking an increase of 1.43%, the current average surpasses the previous average price target of $48.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1733151610_0_1.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Tandem Diabetes Care by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Tandem Diabetes Care's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Tandem Diabetes Care's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
<h2>Discovering Tandem Diabetes Care: A Closer Look</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Financial Milestones: Tandem Diabetes Care's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Tandem Diabetes Care's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 31.43%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Tandem Diabetes Care's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -9.53%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Tandem Diabetes Care's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -9.86%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Tandem Diabetes Care's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.45%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.0, Tandem Diabetes Care faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 8 Analyst Insights On Tandem Diabetes Care

Morgan Stanley analyst Patrick Wood upgrades Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) from Equal-Weight to Overweight and maintains the price target from $45 to $45.

Price Target

Morgan Stanley Upgrades Tandem Diabetes Care to Overweight, Maintains Price Target to $45

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $58 to $60.

Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $60

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Buy and lowers the price target from $57 to $56.

Canaccord Genuity Maintains Buy on Tandem Diabetes Care, Lowers Price Target to $56

Baird analyst Jeff Johnson maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and lowers the price target from $39 to $37.

Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $37

Guidance

Tandem Diabetes Sees FY24 Sales $903M-$910M Vs $890.982M Est

Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.42) by 16.67 percent. The company reported quarterly sales of $244.000 million which beat the analyst consensus estimate of $223.663 million by 9.09 percent. This is a 31.45 percent increase over sales of $185.622 million the same period last year.

Earnings

Earnings Beats

Tandem Diabetes Care Q3 2024 GAAP EPS $(0.35) Beats $(0.42) Estimate, Sales $244.000M Beat $223.663M Estimate

In the last three months, 5 analysts have published ratings on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $48.6, with a high estimate of $65.00 and a low estimate of $42.00. Surpassing the previous average price target of $45.00, the current average has increased by 8.0%.
<img src="https://www.benzinga.com/files/images/story/2024/1730901609_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tandem Diabetes Care. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tandem Diabetes Care. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tandem Diabetes Care's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
<h2>Unveiling the Story Behind Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Unraveling the Financial Story of Tandem Diabetes Care</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Tandem Diabetes Care's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.27% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Tandem Diabetes Care's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -13.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -12.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Tandem Diabetes Care's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.28%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.04, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Tandem Diabetes Care In The Eyes Of 5 Experts

Bernstein analyst Lee Hambright initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Outperform rating and announces Price Target of $42.

Initiation

Bernstein Initiates Coverage On Tandem Diabetes Care with Outperform Rating, Announces Price Target of $42

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst David Roman initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral rating and announced a price target of $46. Tandem Diabetes Care shares fell 1.7% to close at $40.46 on Thursday. <a href="https://www.benzinga.com/quote/TNDM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Laura Prendergast initiated coverage on Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) with a Strong Buy rating and announced a price target of $18. Mural Oncology shares gained 2.6% to close at $3.20 on Thursday. <a href="https://www.benzinga.com/quote/MURA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst George Gianarikas initiated coverage on ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) with a Buy rating and announced a price target of $4.5. ASP Isotopes shares gained 11.1% to close at $3.01 on Thursday. <a href="https://www.benzinga.com/quote/ASPI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Michael Mueller initiated coverage on Curbline Properties Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) with a Overweight rating and announced a price target of $25. Curbline Properties shares gained 4.3% to close at $22.60 on Thursday. <a href="https://www.benzinga.com/quote/CURB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Xiaopo Wei initiated coverage on MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) with a Buy rating and announced a price target of $26.8. MINISO Group shares fell 0.2% to close at $18.96 on Thursday. <a href="https://www.benzinga.com/quote/MNSO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MNSO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-1024x538.png" alt="" class="wp-image-580735" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04091648/image-2-11.png 1278w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41180069/dow-tumbles-nearly-200-points-amid-growing-middle-east-concerns-investor-optimism-declines-fear-ind">Dow Tumbles Nearly 200 Points Amid Growing Middle East Concerns: Investor Optimism Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

ASPI

CURB

MNSO

MURA

This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Goldman Sachs analyst David Roman initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral rating and announces Price Target of $46.

Goldman Sachs Initiates Coverage On Tandem Diabetes Care with Neutral Rating, Announces Price Target of $46

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.
The analyst highlights several key growth drivers for Tandem, positioning it for sustained growth over the coming years driven by expansion into the U.S. Type 1 market with a 40% pump penetration (Tandem has a one-third share), which is expected to rise to the mid-60s and Type 2 market with 6% penetration.
The company is also seeking deeper penetration within existing accounts through product innovations.
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.
GLP-1 drugs such as Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide as Wegovy and Ozempic and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide as Zepbound and Mounjaro, have recently made waves.
RBC analyst highlights that insulin is essential for insulin-dependent patients, as GLP-1 medications cannot regenerate beta cells or halt their deterioration. As a result, the need for insulin remains.
The Type 2 diabetes population, which suffers from irreversible beta cell loss, is underserved.
The growing popularity of GLP-1 drugs may lead to earlier diagnoses of Type 2 diabetes and prompt insulin use, potentially expanding the market.
RBC initiated Tandem with an Outperform, with a price target of $65, citing a significant upside potential driven by earning revisions and multiple expansions.
RBC sees an opportunity for Tandem to achieve profitability over time and projects gross margins of 51% in 2024 or flat y/y to reflect the Mobi launch and investments in several ongoing R&amp;D initiatives.
The analyst sees a clear path for the company to reach its goal of approximately 65% margins, with Mobi accounting for about half of that progress. Further gains are anticipated from planned initiatives.
RBC projects breakeven for 2024, with positive adjusted EBITDA margins expected in the second half of the year.
Price Action: TNDM stock is down 0.37% at $40.92&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41146425/toyota-doubles-down-on-joby-aviation-500m-investment-powers-us-electric-air-taxi-certification-p" target="_blank" rel="noreferrer noopener">Toyota Doubles Down On Joby Aviation: $500M Investment Powers US Electric Air Taxi Certification, Production</a>.</li>
</ul>

Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says

RBC Capital analyst Shagun Singh initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Outperform rating and announces Price Target of $65.

RBC Capital Initiates Coverage On Tandem Diabetes Care with Outperform Rating, Announces Price Target of $65

Analysts' ratings for Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $50.57, along with a high estimate of $58.00 and a low estimate of $39.00. Marking an increase of 7.14%, the current average surpasses the previous average price target of $47.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1727114409_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Tandem Diabetes Care among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Tandem Diabetes Care's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Tandem Diabetes Care's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
<h2>About Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Tandem Diabetes Care displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 13.27%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tandem Diabetes Care's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Tandem Diabetes Care's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -12.92%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.28%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Tandem Diabetes Care's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.04.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 7 Ratings For Tandem Diabetes Care

Morgan Stanley analyst Patrick Wood maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight and maintains $45 price target.

Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target

Tandem's t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin In The European Union

Morgan Stanley analyst Patrick Wood initiates coverage on Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Equal-Weight rating and announces Price Target of $45.

Morgan Stanley Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $45

Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to see following the release of version 2.7.1 of the app in March. Tandem encourages all impacted t:slim X2 iOS users to update their mobile app as soon as the new version is available in the Apple App Store.
Under-delivery of insulin because of a pump shutdown can result in hyperglycemia or diabetic ketoacidosis, which can be a life-threatening condition due to high blood sugar and lack of insulin. There have been 143 confirmed adverse events with this recall. Adverse events are defined as a confirmed high blood sugar and/or an event requiring medical intervention. Two hospitalizations and no deaths have been reported.

AAPL

Tandem Diabetes Care Urges iOS Users to Update App to Prevent Insulin Pump Battery Issues

Canaccord lowered the firm's price target on Tandem Diabetes (TNDM) to $56 from $57 and keeps a Buy rating on the shares. The firm said their thesi...

Tandem Diabetes price target lowered to $56 from $57 at Canaccord

UBS lowered the firm's price target on Tandem Diabetes (TNDM) to $40 from $43 and keeps a Neutral rating on the shares. Despite "another quarterly ...

Tandem Diabetes price target lowered to $40 from $43 at UBS

Barclays analyst Matt Miksic maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target of $60.00. The c...

Barclays Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)

Barclays raised the firm's price target on Tandem Diabetes (TNDM) to $60 from $58 and keeps an Overweight rating on the shares. The company deliver...

Tandem Diabetes price target raised to $60 from $58 at Barclays

Assessing MedTech impact from potential China tariffs

Tandem Diabetes: Recurring Value Erosion, Not Right Point In Cycle To Own

Leerink Partners analyst Mike Kratky maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) on November 25 and set a price target...

Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)

Morgan Stanley upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight. Published first on TheFly – the ultimate source for real-time, mark...

Tandem Diabetes upgraded to Overweight from Equal Weight at Morgan Stanley

As previously reported, Morgan Stanley upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with an unchanged price target of $45. The s...

Morgan Stanley upgrades 'too cheap' Tandem Diabetes to Overweight

Morgan Stanley bullish on medtech in 2025, upgrades 5 stocks

BLCO

GEHC

MASI

NVST

SOLV

Press Releases

Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance

Legal

TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Tandem Diabetes Care

Actualités

Dernières nouvelles pour Tandem Diabetes Care (NASDAQ:TNDM) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL